Candel Therapeutics (CADL) Equity Average (2020 - 2025)

Candel Therapeutics has disclosed Equity Average across 6 years of filings, most recently posting $66.0 million for Q4 2025.

• Equity Average for Q4 2025 came in at $66.0 million, up 158.56% year-over-year; the trailing twelve-month figure through Dec 2025 was $66.0 million (up 158.56% YoY), and the FY2025 annual result was $59.1 million, up 49.55% from the prior year.
• Equity Average came in at $66.0 million for Q4 2025 at Candel Therapeutics, down from $85.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $85.2 million in Q3 2025 to a low of -$35.3 million in Q2 2021.
• The 5-year median for Equity Average is $39.4 million (2023), against an average of $34.6 million.
• Across the five-year window, Equity Average slumped 146.9% in 2024 and surged 4229.35% in 2025, its largest moves.
• Candel Therapeutics' Equity Average stood at $63.6 million in 2021, then decreased by 21.46% to $49.9 million in 2022, then tumbled by 64.18% to $17.9 million in 2023, then soared by 42.79% to $25.5 million in 2024, then soared by 158.56% to $66.0 million in 2025.
• The last three Equity Average figures came in at $66.0 million (Q4 2025), $85.2 million (Q3 2025), and $82.4 million (Q2 2025), per Business Quant data.